Image Source: Zacks Investment Research Under its ... Based on the above study results, SAVA had discontinued the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now ...

SAVA has a new potential indication for simufilam, the treatment of seizures related to tuberous sclerosis complex, although the company is not yet running a clinical trial here. SAVA isn't done ...